奥氮平与利培酮治疗首次发病未服药精神分裂症患者起效时间及对疗效预测作用的比较

The predictive value of time to treatment response in antipsychotic-naive patients with first-episode schizophrenia: A comparative study of olanzapine and risperidone

目的:比较奥氮平与利培酮治疗首发精神病患者早期改善对临床疗效的预测。方法:80例首发从未服药精神分裂症患者随机分为只接受奥氮平治疗(奥氮平组,39例)和利培酮治疗(利培酮组,41例),疗程8周。每周采用阳性和阴性症状量表(PANSS)对患者精神症状进行评定。结果:利培酮治疗第2周(OR=0. 001,95%CI:0. 000～0. 154;χ2=6. 188,P=0. 033),奥氮平第3周(OR=0. 002,95%CI:0. 000～0. 216:χ2=6. 583,P=0. 010)精神症状的改善是药物疗效的保护因素。结论:利培酮组第2周和奥氮平组第3周的早期应答均能有效地预测药物治疗第8周的结果,早期治疗的改善可以作为预测药物疗效的指标之一。

Objective:To explore the predictive value of early treatment response in antipsychotic-naive patients with first-episode psychosis:olanzapine versus risperidone. Method:80 antipsychotic-naive,first-episode schizophrenia inpatients were divided into two groups:olanzapine for 39 cases and risperidone for 41 cases.Patients were assessed weekly using the positive and negative syndrome scale(PANSS).Results:In the risperidone group,week 2 improvement predicted improvement at week 8(OR=0.001,95%CI:0.000~0.154,χ2=6.188,P=0.033).In the olanzapine group,week 3 improvement predicted improvement at week 8(OR=0.002,95%CI:0.000~0.216,χ2=6.583,P=0.010).Conclusion:Early response at week 2 in the risperidone group and week 3 in the olanzapine group predicted treatment outcomes,suggesting early treatment response is a predictor of therapeutic efficacy in schizophrenia.